Circulate Health, a startup focused on leveraging therapeutic plasma exchange (TPE) to enhance healthspan and lifespan, has raised $12 million in seed funding, led by Khosla Ventures with participation from Seaside Ventures and CSC Ventures.
TPE is a procedure that removes and replaces a patient’s plasma to treat inflammation and chronic diseases. Circulate Health has been quietly researching the benefits of TPE for three years and has partnered with clinics to provide this treatment across the U.S. and plans international expansion.
Founded by renowned geroscientist Eric Verdin, MD, Circulate recently published a clinical trial showing that TPE combined with intravenous immunoglobulin (IVIG) can reduce patients’ biological age by an average of 2.6 years. The company’s scientific advisory board includes experts like Matt Kaeberlein, PhD, and Alex Aravanis, MD, PhD.
Circulate currently operates with 24 partner clinics across eight states, with plans to expand to over 50 clinics by the end of 2025, both domestically and internationally.
KEY QUOTES:
“We have been immensely dedicated to our research and delivering the highest quality medical care to patients and clinic partners in order to further address healthspan, and the hallmarks of aging. Khosla Ventures’ investment into our work truly demonstrates the power of and potential for the work we’re doing. We plan to use these additional funds to expand our clinic network across the country and internationally, and provide greater access to those seeking access to a therapy shown to improve biomarkers and biological clocks.”
Brad Younggren, MD, CEO and co-founder of Circulate
“We incubated Circulate to explore whether a safe, well-understood therapy like TPE could counter the deleterious effects of aging, and offer broader health benefits like potentially removing microplastics from the body. Early clinical results are promising, and we’re excited to continue backing the team as they work to make TPE more accessible to more people.”
Alex Morgan of Khosla Ventures
